14. Aging and Androgen Augmentation Therapy หนา 14 จาก 17
สรางโดย Thanaboon Chulyamitporn D:andropauseLOHcarePMK21-07-2006.doc
Injectable testosterone in solution 10-50 mg i.m. every 2 days
testosterone cypionate (in oil suspension) 50-250 mg i.m. every 2 weeks
testosterone propionate (in oil suspension) 10-25 mg i.m. twice a week
testosterone enanthate (in oil suspension) 50-250 mg i.m. every 2 weeks
testosterone undecanoate (in oil suspension) 1000 mg every 10-14 weeks
Oral testosterone undecanoate capsules (in oleic acid) 80-200 mg/day
testosterone undecanoate capsules (in a mixture of
castor oil & propylene glycol laurate)
initially: 120-160 mg/day for 2-3
weeks, then 40-120 mg/day
fluoxymesterone* 2.5-20 mg/day
methyltestosterone* 10-20 mg/day
mesterolone 75-150 mg/day
buccal testosterone buccal system 30 mg/twice a day
transdermal testosterone patch 5 mg/day
testosterone gel 5 g of 1% testosterone gel
subcutanous pellets of crystalline testosterone 600 mg every 4-6 months
* หามใชเพราะมีพิษตอตับ
15. Aging and Androgen Augmentation Therapy หนา 15 จาก 17
สรางโดย Thanaboon Chulyamitporn D:andropauseLOHcarePMK21-07-2006.doc
Reference List
1. Walker RF. Is aging a disease? A review of the Serono Symposia Workshop held under the auspices of the 3rd
World Congress on the Aging Male. February 9, 2002, Berlin, Germany. Aging Male 2002;5:147-69.
2. United Nations. World Population Prospects, The 1998 Revision. 1999. New York, United Nations.
3. ธนบูรณ จุลยามิตรพร, สายัณห สวัสดิ์ศรี, บัณฑิต จันทะยานี. เทสทอสเตอโรนกับชายวัยทอง. In:
บัณฑิต จันทะยานี, สายัณห สวัสดิ์ศรี, ธนบูรณ จุลยามิตรพร, บัณฑิต กาญจนพยัฆ, อยุทธินี สิงหโก
วินท, เจษฎา อุดมมงคล, editors. Aging male: men's health through the ages. กรุงเทพฯ: บียอนด เอ็นเทอร
ไพรช; 2544. หนา66-74.
4. Kaufman J. Hypothalamic-pituitary-gonadal function in aging men. Aging Male 1999;2:157.
5. Morales A, Lunenfeld B. Investigation, treatment and monitoring of late-onset hypogonadism in males. Official
recommendations of ISSAM. International Society for the Study of the Aging Male. Aging Male. 2002;5:74-86.
6. หะทัย เทพพิสัย. Overview ADAM vs PADAM in Thailand. In: บัณฑิต จันทะยานี, สายัณห สวัสดิ์ศรี, ธน
บูรณ จุลยามิตรพร, บัณฑิต กาญจนพยัฆ, อยุทธินี สิงหโกวินท, เจษฎา อุดมมงคล, editors. Aging male:
men's health through the ages. กรุงเทพฯ: บียอนด เอ็นเทอรไพรช; 2544. หนา66-74.
7. Lunenfeld B. Hormone replacement therapy in the aging male. Aging Male 1999;2:1-5.
8. ภักดี โพธิศิริ. Policies issues for the aging male in Thailand. In: สายัณห สวัสดิ์ศรี, บัณฑิต จันทะยานี,
บัณฑิต กาญจนพยั, ธนบูรณ จุลยามิตรพร, ชาติวุฒิ ค้ําชู, อยุธินี สิงหโกวินท et al, editors. Aging male II:
problems practice promotion prevention postpone productivity. กรุงเทพฯ: บียอนด เอ็นเทอรไพรช; 2545.
หนา3-12.
9. Vermeulen A, Kaufman JM. Aging of the hypothalamopituitary-testicular axis in men. Horm Res 1995;43:25-28.
10. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ et al. Investigation, treatment and
monitoring of late-onset hypogonadism in males. Aging male. 2005; 8:56-8.
11. Vermeulen A, Rubens R, Verdonck L. Testosterone secretion and metabolism in male senescence. J Clinic
Endocrinol Metab 1972;34:730-35.
12. Stearns EL, MacDonnell JA, Kaufman BJ, Padua R, Lucman TS, Winter JS et al. Declining testicular function
with age. Hormonal and clinical correlates. Am J Med 1974;57:761-66.
16. Aging and Androgen Augmentation Therapy หนา 16 จาก 17
สรางโดย Thanaboon Chulyamitporn D:andropauseLOHcarePMK21-07-2006.doc
13. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free
testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001;86:724-
31.
14. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D et al. Validation of a screening questionnaire
for androgen deficiency in aging males. Metabolism 2000;49:1239-42.
15. Lunenfeld B. Aging men--challenges ahead. Asian J.Androl 2001;3:161-68.
16. Lunenfeld B, Saad F, Hoesl CE. ISA, ISSAM and EAU recommendations for the investigation, treatment and
monitoring of late-onset hypogonadism in males: scientific background and rationale. Aging male 2005;8:59-74.
17. Heinemann, L. J., Zimmermann, T., Vermeulen, A., Thiel, C., and Hummel, W. A new aging males symptoms
rating scale. The Aging Male 2, 105-114. 1999.
18. Daig I, Heinemann LA, Kim S, Leungwattanakij S, Badia X, Myon E et al. The Aging Males' Symptoms (AMS)
scale: review of its methodological characteristics. Health Qual.Life Outcomes. 2003;1:77.
19. Kratzik CW, Reiter WJ, Riedl AM, Lunglmayr G, Brandstätter N, Rücklinger E, Metka M, Huber J. Hormone
profiles, body mass index and Aging Male Symptoms results of the Androx Vienna Municipality study. Aging
Male 2004;7:188-96.
20. T’Sjoen G, Feyen E, Kuyper P, Comhaire F, Kaufman JM. Self-referred patients in an aging male clinic: much
more than androgen deficiency alone. Aging Male 2003;6:157-65.
21. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free
testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-72.
22. Oettel M. Is there a role for estrogens in the maintenance of men's health? Aging Male 2002;5:248-57.
23. Gooren L, Lunenfeld B. Screening of the aging male. In: Lunenfeld B, Gooren L, editors. Textbook of Men's
Health. New York: The Parthenon Publishing Group; 2002. p. 15-43.
24. Abrams P, Blaivas J, Griffiths D. The Objective evaluation of bladder outlet obstruction (urodynamics). In:
Cockett A, Houry S, Aso Y, et al, editors. The second International Consultation on Benign Prostate Hyperplasia
(BPH). Channel Islands: Scientific Communications International; 1993. p. 115.
25. Kim YC. Hormonal replacement therapy and aging: Asian practical recommendations on testosterone
supplementation. Asian J.Androl 2003;5:339-44.
26. Handelsman DJ, Zajac JD. Androgen deficiency and replacement therapy in men. Med.J.Aust. 2004;180:529-35.
17. Aging and Androgen Augmentation Therapy หนา 17 จาก 17
สรางโดย Thanaboon Chulyamitporn D:andropauseLOHcarePMK21-07-2006.doc
27. Wang C, Swerdloff R, Kipnes M, Matsumoto AM, Dobs AS, Cunningham G et al. New testosterone buccal system
(Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men.
J.Clin.Endocrinol.Metab 2004;89:3821-29.
28. Leder BZ, Rohrer JL, Rubin SD, Gallo J, Longcope C. Effects of aromatase inhibition in elderly men with low or
borderline-low serum testosterone levels. J.Clin.Endocrinol.Metab 2004;89:1174-80.
29. Bhasin S, Bagatell CJ, Bremner WJ, Plymate SR, Tenover JL, Korenman SG et al. Issues in testosterone
replacement in older men. J Clin Endocrinol Metab 1998;83:3435-48.
30. Oettel M. Testosterone metabolism, dose-response relationships and receptor polymorphisms: selected
pharmacological/toxicological considerations on benefits versus risks of testosterone therapy in men. Aging Male
2003;6:230-56.
31. Laseter JT, Russel JA. Anaboloic steroid-induced tendon pathology: a review literature. Med Sci Sports Exerc
1991;23:1-3.
32. Snyder PJ. Delvelopment of criteria to monitor the occurrence of prostate cancer in testosterone clinical trial. In:
Bhasin S, Gabelnick HL, Swoerdloff RS, Wang C, editors. Pharmacology, Biology, and Clinical Applications of
Androgens. New York: Wiley-Liss; 1996. p. 143-50.